Merck and Eisai announced on January 24, 2025, mixed results from a late-stage trial evaluating their cancer drugs Keytruda and Lenvima in combination with chemotherapy. The study focused on patients with a type of esophageal cancer.
While the Phase 3 study showed a statistically significant improvement in progression-free survival (PFS), one of its dual primary endpoints, it missed the other primary endpoint of overall survival (OS). This outcome indicates that the combination did not extend patients' lives significantly.
The safety profile of Keytruda plus Lenvima in the study was consistent with previously reported data. A full evaluation of the study data is ongoing, which will determine the future development strategy for this combination in esophageal cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.